Released May 14, 2021, before the open
10-Q filed May 14, 2021, 44 days after period end · 0001558370-21-007157
Q1 2021 · 10-Q
Revenue$11.32M$11.32M −47.7% vs Q1 2020−41.9% vs Q4 2020
Net Income-$5.48M-$5.48M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.14-$0.14 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$3,705,000N/M
Operating Cash Flow-$9,834,000N/M
Free Cash Flowderived-$10,220,000N/M
Margins · derived
Operating margin-32.7%−54.4 pt vs Q1 2020
Net margin-48.4%−56.1 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $11.32M | $21.65M | $10.44M | $4.55M |
| Net Income | -$5.48M | $1.67M | -$7.26M | -$7.24M |
| EPS Diluted | -$0.14 | $0.10 | -$0.50 | -$0.50 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR